At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.
To tackle these challenges, we are advancing an innovative pipeline of multi-modal small molecules all with novel mechanisms of action and a precision therapeutic approach. Our approach to developing therapeutics delivered locally to the site of inflammation is clinically and scientifically differentiated.
ADS051 is a first-in-class, oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis that has completed a Phase 1b MAD clinical trial and will be moving into Phase 2 development later this year. Adiso is also developing ADS032, a first-in-class small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1) and is in advanced pre-clinical development for the treatment of respiratory and dermal inflammation.